FDA Issues Untitled Letter for Avodart TV Spot

A TV commercial that claims GlaxoSmithKline’s (GSK) Avodart is the only medicine that treats the cause of urinary symptoms associated with an enlarged prostate was cited by the FDA for allegedly making misleading claims and overstating the product’s efficacy. The FDA cites the comparative claim in an untitled letter to GSK, highlighting another drug in the same pharmacological class as Avodart that it approved for symptomatic benign prostatic hyperplasia.
Washington Drug Letter